Pharmaceutical excipient having improved compressability
January 9, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3141875 Novel excipient and pharmaceutical composition containing the same Compressed and formed alkaline component suitable for use in buffered aspirin product Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation Cellulosic dosage form Controlled release tablet containing water soluble medicament Process for the preparation of a tablet or dragee composition containing a heat-, light- and moisture-sensitive active ingredient having monoclinic crystal structure Patent #: 5322698 InventorsAssigneeApplicationNo. 370576 filed on 01/09/1995US Classes:424/489, Particulate form (e.g., powders, granules, beads, microcapsules, and pellets)424/469, Discrete particles in supporting matrix424/470, Where particles are granulated424/480, Cellulose or derivative424/494Cellulose derivativesExaminersPrimary: Page, Thurman K.Assistant: Benston, William E. Jr. Attorney, Agent or FirmForeign Patent References
International ClassA61K 009/14AbstractA microcrystalline cellulose-based excipient having improved compressibility, whether utilized in direct compression, dry granulation or wet granulation formulations, is disclosed. The excipient is an agglomerate of microcrystalline cellulose particles and from about 0.1% to about 20% silicon dioxide particles, by weight of the microcrystalline cellulose, wherein the microcrystalline cellulose and silicon dioxide are in intimate association with each other. The silicon dioxide utilized in the novel excipient has a particle size from about 1 nanometer to about 100 microns. Most preferably, the silicon dioxide is a grade of colloidal silicon dioxide. | |
